These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 32845786

  • 21. Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.
    Jain R, Babcock T, Burtea T, Dirks B, Adeyi B, Scheckner B, Lasser R, Renna J, Duncan D.
    Adv Ther; 2013 May; 30(5):472-86. PubMed ID: 23681505
    [Abstract] [Full Text] [Related]

  • 22. Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials.
    Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P.
    Drug Des Devel Ther; 2015 May; 9():1927-36. PubMed ID: 25897203
    [Abstract] [Full Text] [Related]

  • 23. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder MH.
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [Abstract] [Full Text] [Related]

  • 24. Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.
    Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A.
    J Cent Nerv Syst Dis; 2017 Sep; 9():1179573517728090. PubMed ID: 28855799
    [Abstract] [Full Text] [Related]

  • 25. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
    Adler LA, Dirks B, Deas P, Raychaudhuri A, Dauphin M, Saylor K, Weisler R.
    BMC Psychiatry; 2013 Oct 09; 13():253. PubMed ID: 24106804
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
    Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Chan D, Childress A.
    J Manag Care Spec Pharm; 2024 Jun 09; 30(6):528-540. PubMed ID: 38824626
    [Abstract] [Full Text] [Related]

  • 28. A systematic review of the safety of lisdexamfetamine dimesylate.
    Coghill DR, Caballero B, Sorooshian S, Civil R.
    CNS Drugs; 2014 Jun 09; 28(6):497-511. PubMed ID: 24788672
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL.
    Clin Ther; 2007 Mar 09; 29(3):450-63. PubMed ID: 17577466
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, Childress AC.
    J Child Adolesc Psychopharmacol; 2013 Feb 09; 23(1):11-21. PubMed ID: 23410138
    [Abstract] [Full Text] [Related]

  • 33. Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis.
    Fridman M, Hodgkins PS, Kahle JS, Erder MH.
    Eur Psychiatry; 2015 Jun 09; 30(4):521-7. PubMed ID: 25725594
    [Abstract] [Full Text] [Related]

  • 34. Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder.
    Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Fukushi A, Saito K.
    Neuropsychopharmacol Rep; 2020 Mar 09; 40(1):52-62. PubMed ID: 31814294
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Banaschewski T, Johnson M, Lecendreux M, Zuddas A, Adeyi B, Hodgkins P, Squires LA, Coghill DR.
    CNS Drugs; 2014 Dec 09; 28(12):1191-203. PubMed ID: 25139785
    [Abstract] [Full Text] [Related]

  • 37. A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy.
    Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Qu A, Lee F, Childress A.
    J Comp Eff Res; 2024 Sep 09; 13(9):e240089. PubMed ID: 39132746
    [Abstract] [Full Text] [Related]

  • 38. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
    Childress AC, Arnold V, Adeyi B, Dirks B, Babcock T, Scheckner B, Lasser R, Lopez FA.
    J Atten Disord; 2014 Feb 09; 18(2):123-32. PubMed ID: 22740112
    [Abstract] [Full Text] [Related]

  • 39. Post hoc analyses of response rates to pharmacological treatments in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill DR, Newcorn JH, Chen J, Werner-Kiechle T, Banaschewski T.
    J Psychopharmacol; 2020 Aug 09; 34(8):874-882. PubMed ID: 32043417
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of a head-to-head study of lisdexamfetamine dimesylate and atomoxetine: evaluation of Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomised, double-blind, Phase IIIb study. CNS Drugs 2013;27:1081-1092. doi: 10.1007/s40263-013-0104-8 ClinicalTrials.gov: NCT01106430.
    Banaschewski T, Rothermel B, Poustka L.
    Expert Opin Pharmacother; 2014 Sep 09; 15(13):1961-5. PubMed ID: 25085429
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.